Affiliation:
1. Cancer Epidemiology Branch, Division of Cancer Epidemiology and Prevention, National Cancer Center, 323 Ilsandong-gu, Goyang-si 10408, Republic of Korea
2. Department of Urology, Center for Urologic Cancer, Research Institute, Hospital of National Cancer Center, 323 Ilsandong-gu, Goyang-si 10408, Republic of Korea
Abstract
Non-invasive diagnostics are crucial for the timely detection of renal cell carcinoma (RCC), significantly improving survival rates. Despite advancements, specific lipid markers for RCC remain unidentified. We aimed to discover and validate potent plasma markers and their association with dietary fats. Using lipid metabolite quantification, machine-learning algorithms, and marker validation, we identified RCC diagnostic markers in studies involving 60 RCC and 167 healthy controls (HC), as well as 27 RCC and 74 HC, by analyzing their correlation with dietary fats. RCC was associated with altered metabolism in amino acids, glycerophospholipids, and glutathione. We validated seven markers (l-tryptophan, various lysophosphatidylcholines [LysoPCs], decanoylcarnitine, and l-glutamic acid), achieving a 96.9% AUC, effectively distinguishing RCC from HC. Decreased decanoylcarnitine, due to reduced carnitine palmitoyltransferase 1 (CPT1) activity, was identified as affecting RCC risk. High intake of polyunsaturated fatty acids (PUFAs) was negatively correlated with LysoPC (18:1) and LysoPC (18:2), influencing RCC risk. We validated seven potential markers for RCC diagnosis, highlighting the influence of high PUFA intake on LysoPC levels and its impact on RCC occurrence via CPT1 downregulation. These insights support the efficient and accurate diagnosis of RCC, thereby facilitating risk mitigation and improving patient outcomes.
Funder
National Cancer Center, Republic of Korea
Reference52 articles.
1. Kidney cancer biomarkers and targets for therapeutics: Survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma;Li;J. Exp. Clin. Cancer Res.,2021
2. Genetic and metabolic hallmarks of clear cell renal cell carcinoma;Sanchez;Biochim. Et Biophys. Acta (BBA) Rev. Cancer,2018
3. Perrotti, F., Rosa, C., Cicalini, I., Sacchetta, P., Del Boccio, P., Genovesi, D., and Pieragostino, D. (2016). Advances in lipidomics for cancer biomarkers discovery. Int. J. Mol. Sci., 17.
4. Current evidence on screening for renal cancer;Simmons;Nat. Rev. Urol.,2020
5. Urine metabolomics for renal cell carcinoma (RCC) prediction: Tryptophan metabolism as an important pathway in RCC;Liu;Front. Oncol.,2019